Janux Therapeutics, Inc.
JANX
$16.12
$0.120.75%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 2.89% | -47.25% | -64.69% | -68.32% | -139.85% |
| Total Depreciation and Amortization | -8.69% | -3.32% | -1.50% | -0.29% | 0.63% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -17.17% | -9.04% | 0.94% | -7.21% | 144.24% |
| Change in Net Operating Assets | 130.35% | 163.00% | 880.15% | 14,378.79% | 198.39% |
| Cash from Operations | 31.01% | -68.58% | -87.69% | -90.37% | -28.68% |
| Capital Expenditure | 26.02% | -77.30% | -190.53% | -17.67% | 28.66% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 102.75% | 110.05% | -16.41% | -5.58% | 17.63% |
| Cash from Investing | 102.52% | 109.84% | -16.65% | -5.62% | 17.67% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -97.64% | -97.98% | -99.26% | 18.81% | 2.03% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | 100.00% | -- | -- | -- |
| Cash from Financing | -97.63% | -97.97% | -99.31% | 18.70% | 1.94% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -165.31% | 84.24% | -191.95% | 125.32% | 298.43% |